Article

Multi-omics alleviates the limitations of panel-sequencing for cancer drug response prediction

2022-06-17

Abstract excerpt

Comprehensive genomic profiling using cancer gene panels has been shown to improve treatment options for a variety of cancer types. However, genomic aberrations detected via such gene panels don’t necessarily serve as strong predictors of drug sensitivity. In this study, using pharmacogenomics datasets of cell lines, patient-derived xenografts, and ex-vivo treated fresh tumor specimens, we demonstrate that utiliz...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 95229574-fdb0-52d4-a98c-6bd29f4efdd7
DOI: 10.1101/2022.06.15.496249

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Multi-omics alleviates the limitations of panel-sequencing for cancer drug response predictionDOI 10.1101/2022.06.15.496249Read

Translational and clinical comparison of whole genome and transcriptome to panel sequencing in precision oncologySemantic proximity Read

Cancer Treatment in the Genomic EraSemantic proximity Read

Comparison of whole-exome, whole-transcriptome genomic profiling and targeted sequencing with 50-gene panels in advanced solid tumorsSemantic proximity Read

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancerSemantic proximity Read

Drug Sensitivity Prediction From Cell Line-Based Pharmacogenomics Data: Guidelines for Developing Machine Learning ModelsSemantic proximity Read

Whole-genome and transcriptome analysis enhances precision cancer treatment options.Semantic proximity Read

Predicting patient treatment response and resistance via single-cell transcriptomics of their tumorsSemantic proximity Read

Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbations.Semantic proximity Read

SeqOIA platform, an integrative and interactive approach to optimize personalized cancer treatmentSemantic proximity Read

Personalized cancer therapy-leveraging a knowledge base for clinical decision-making.Semantic proximity Read

Dr.Paso: Drug response prediction and analysis system for oncology researchSemantic proximity Read

Incorporating tumor genomic profiling and drug screening through circulating tumor cell- derived organoids into clinical practice for the management of Gastrointestinal CancersSemantic proximity Read